| GBT Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the GBT market cap history going back to 8/12/2015:
Also see: GBT Shares Outstanding History and GBT YTD Return |
GBT Market Cap History — Global Blood Therapeutics Capitalization Over Time
As of 8/4/2022 Global Blood Therapeutics has a market cap of 3.24 billion. Investors often follow the GBT market cap history to compare the size of the company over time.
This page shows GBT market capitalization trends over time, with 31 market cap datapoints presented, dating back to 8/12/2015.
| GBT Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GBT Historical Market Cap: +15.29% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GBT Stock Price Chart |
| About Global Blood Therapeutics Inc |
| Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601. We show 31 historical shares outstanding datapoints in our GBT shares outstanding history coverage, used to compute GBT market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing GBT market cap history over the course of time is important for investors interested in comparing GBT's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of GBT versus a peer is one thing; comparing GBT market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like GBT can fluctuate over the course of history. With this page we aim to empower investors researching GBT by allowing them to research the GBT market cap history. |
| GBT Current Stock Quote |
Quotes delayed 20 minutes  Free GBT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| GBT Share Performance |
| Market Cap Peers |
| Global Blood Therapeutics (GBT) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
GCTK Market Cap History GEHC Market Cap History GEMP Market Cap History GENE Market Cap History GERN Market Cap History GFOR Market Cap History GH Market Cap History GHDX Market Cap History GILD Market Cap History GKOS Market Cap History More Healthcare companies » |
GBT Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
